Cortexyme successfully completes acquisition of novosteo

South san francisco, calif.--(business wire)--cortexyme, inc. (nasdaq: crtx), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion of its acquisition of novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury. novosteo stockholders now own approximately 15.5% of the combined company. with the com
QNCX Ratings Summary
QNCX Quant Ranking